Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)
Tralokinumab monotherapy was well tolerated, and superior to placebo at 16 weeks for IGA score of 0/1 and EASI 75 response in both studies (15.8% vs 7.1% & 25.0% vs 12.7% respectively for ECZTRA 1 [n=802]; 2.2% vs 10.9% & 33.2% vs 11.4% for ECZTRA 2 [n=794] [all p<0.002]).
Source:
British Journal of Dermatology
SPS commentary:
Tralokinumab is an investigational fully human monoclonal antibody that neutralizes interleukinâ13, a key cytokine driving peripheral inflammation in atopic dermatitis.
The ECZTRA 3 trial reported significant improvements at week 16 with tralokinumab in conjunction with topical corticosteroids vs placebo (n=380; IGA 0/1 = 38.9% vs. 26.2%; [p = 0.015] and EASI 75 reponse: 56.0% vs. 35.7%; p < 0.001].